Bevacizumab/IrinotecanLack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2024卷 / 1期

关键词：

D O I：

10.1007/s40278-024-66073-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：91 / 91

相关论文

共 50 条

[41] Bevacizumab/carboplatin/vinorelbineLack of efficacy: case report
Reactions Weekly, 2022, 1917 (1) : 128 - 128
[42] Aumolertinib/bevacizumab/pemetrexedLack of efficacy: case report
Reactions Weekly, 2022, 1908 (1) : 92 - 92
[43] Bevacizumab/cabozantinib/erlotinibLack of efficacy: case report
Reactions Weekly, 2023, 1981 (1) : 91 - 91
[44] Carboplatin/etoposide/irinotecanLack of efficacy and death: 2 case reports
Reactions Weekly, 2022, 1910 (1) : 124 - 124
[45] Fluorouracil/folinic acid/irinotecanLack of efficacy: 2 case reports
Reactions Weekly, 2023, 1960 (1) : 206 - 206
[46] Bevacizumab/cisplatin/lomustineMyelosuppression and lack of efficacy: case report
Reactions Weekly, 2023, 1946 (1) : 117 - 117
[47] Bevacizumab/lomustine/temozolomideLack of efficacy and pneumonitis: case report
Reactions Weekly, 2022, 1929 (1) : 143 - 143
[48] Atezolizumab/bevacizumab/methylprednisolonePneumonitis and lack of efficacy: case report
Reactions Weekly, 2021, 1862 (1) : 79 - 79
[49] Antineoplastics/bevacizumab/catequentinibPneumothorax and lack of efficacy: case report
Reactions Weekly, 2022, 1918 (1) : 70 - 70
[50] Bevacizumab/carboplatin/nivolumab/pemetrexedLack of efficacy: case report
Reactions Weekly, 2022, 1923 (1) : 106 - 106

← 1 2 3 4 5 →